Radiant Biotherapeutics, an antibody platform company developing multi-valent, multi-specific therapeutics, has unveiled an $8 million seed financing and two pharmaceutical partnerships. Radiant is based on foundational IP from the labs of Dr. Jean-Philippe Julien at The Hospital for Sick Children (SickKids) and Dr. Bebhinn Treanor at the University of Toronto. It was created by Amplitude Ventures which also led the seed round along with launch partner, SickKids and investors Alexandria Investments, FACIT and Toronto Innovation Acceleration Partners (TIAP).
 
Radiant’s Multabody platform exploits avidity – stronger binding power – coupled with multi-specificity to deliver highly efficacious antibodies with exceptional potency extending beyond today’s antibody technologies to overcome the limitations of current approaches. This platform has demonstrated the potential to deliver a new class of multi-functional biologics to tackle complex and diverse diseases, including cancer, autoimmune conditions and infectious diseases. Built on an antibody framework, the Multabody retains monoclonal antibody-like developability and pharmacokinetics, creating a superior next-generation therapeutic.

“This financing enables us to advance and validate our Multabody platform among several oncology programs with potential best-in-class profiles,” said Arthur J. Fratamico, President and Chief Executive Officer of Radiant. “We are maximizing the potential of the Multabody platform by building a pipeline of candidates in our therapeutic areas of focus and pursuing additional research collaborations outside of those areas. The interest we received from potential partners to date is significant, resulting in two undisclosed collaborations with global pharma partners.”